50. Dermatomyositis Clinical trials / Disease details
Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04723303 (ClinicalTrials.gov) | October 6, 2021 | 8/12/2020 | Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) | Phase 1 Study of Mesenchymal Stromal Cells, Umbilical Cord Lining Stem Cells (ULSC), in Patients With Polymyositis (PM) and Dermatomyositis (DM) | Polymyositis;Dermatomyositis | Drug: Umbilical Cord Lining Stem Cells | University of Florida | Restem, LLC. | Active, not recruiting | 18 Years | 90 Years | All | 10 | Early Phase 1 | United States |